Alembic Pharma gets USFDA nod for its antibiotic capsules

Drug firm Alembic Pharmaceuticals today said it has received approval from the US health regulator for its Doxycycline Hyclate capsules used for treatment of wide variety of bacterial infections.

The approval from the United States Food and Drug Administration (USFDA) is for the company’s abbreviated new drug application (ANDA) for Doxycycline Hyclate capsules USP, in the strengths of 50 mg and 100 mg, Alembic Pharmaceuticals said in a filing to BSE.

The product is generic version of Pfizer Inc’s Vibramycin capsules in the same strengths, it added.

“Doxycycline Hyclate capsules USP, 50 mg and 100 mg, have an estimated market size of USD 80 million for twelve months ending December 2017, according to IQVIA,” Alembic Pharma said.

The company currently has a total of 73 ANDA approvals (65 final approvals and 8 tentative approvals) from USFDA, it added.

Shares of Alembic Pharmaceuticals today closed at Rs 506.55 per scrip on BSE, up 3.32 per cent from its previous close.

  • Related Posts

    Licences of 20 medical stores suspended after inspections

    Drug Control Department inspects 120 medical stores; 32 NDPS cases and 63 arrests recorded in 2026 so far The district administration has intensified action against illegal drug sale and distribution,…

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    NEW DELHI: Global investment firm Bain Capital has divested nearly a 1 per cent stake in Emcure Pharmaceuticals for over Rs 289 crore through open market transactions, according to the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert

    Civil society group SAM calls for greater transparency involving clinical trials

    Civil society group SAM calls for greater transparency involving clinical trials

    Different packaging, typos expose fake Mounjaro racket

    Different packaging, typos expose fake Mounjaro racket